vTv Therapeutics Company Profile (NASDAQ:VTVT)

Analyst Ratings

Consensus Ratings for vTv Therapeutics (NASDAQ:VTVT) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.25 (240.11% upside)

Analysts' Ratings History for vTv Therapeutics (NASDAQ:VTVT)
Show:
DateFirmActionRatingPrice TargetActions
12/17/2015Janney Montgomery ScottInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2015Canaccord GenuityInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/24/2015Piper Jaffray Cos.Initiated CoverageOverweight$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/24/2015Stifel NicolausInitiated CoverageBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2014 forward)

Earnings

Earnings History for vTv Therapeutics (NASDAQ:VTVT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/1/2016        
5/12/2016Q1($0.54)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2016Q4($0.47)($0.35)$0.03 million$0.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for vTv Therapeutics (NASDAQ:VTVT)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for vTv Therapeutics (NASDAQ:VTVT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for vTv Therapeutics (NASDAQ:VTVT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/27/2016Paul G SavasDirectorBuy6,000$5.67$34,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Paul G SavasDirectorBuy1,259$5.26$6,622.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2016Ronald O PerelmanMajor ShareholderBuy10,000$4.99$49,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Ronald O PerelmanMajor ShareholderBuy400,000$5.20$2,080,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2016Paul G SavasDirectorBuy10,000$5.35$53,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.64$56,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Paul G SavasDirectorBuy15,000$5.82$87,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.83$58,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2016Ronald O PerelmanMajor ShareholderBuy10,000$6.43$64,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2016Ronald O PerelmanMajor ShareholderBuy20,000$6.05$121,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2016Ronald O PerelmanMajor ShareholderBuy15,000$6.41$96,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2015Ronald O PerelmanMajor ShareholderBuy15,000$6.40$96,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Noel Joseph SpiegelDirectorBuy5,710$6.20$35,402.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015Ronald O PerelmanMajor ShareholderBuy30,000$6.26$187,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Ronald O PerelmanMajor ShareholderBuy40,000$6.04$241,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Paul G SavasDirectorBuy5,000$6.62$33,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2015Ronald O PerelmanMajor ShareholderBuy24,000$6.82$163,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for vTv Therapeutics (NASDAQ:VTVT)
DateHeadline
07/27/16 07:40 PMvTv Therapeutics Announces Presentation of Phase 2b Azeliragon Results at the 2016 Alzheimer's Association International Conference (AAIC)
07/27/16 07:40 PMvTv Therapeutics (VTVT) Announces Presentation of Phase 2b Azeliragon Results at AAIC
07/27/16 04:38 PMvTv Therapeutics Announces Presentation of Phase 2b Azeliragon Results at the 2016 Alzheimer’s Association International Conference (AAIC) - [at noodls] - Analysis shows azeliragon 5mg/day resulted in steadily increasing delay in time to cognitive deterioration in mild Alzheimer's disease patients Azeliragon designed to inhibit RAGE, which affects Aβ accumulation, ...
07/22/16 02:28 PMETF’s with exposure to vTv Therapeutics, Inc. : July 22, 2016 -
07/20/16 08:17 PMvTv Therapeutics : U.S. Patents Awarded to Inventors in Maryland (July 20)
07/14/16 10:50 AMvTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral Presentation at the 2016 Alzheimer's Association International Conference
07/14/16 08:28 AMvTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral Presentation at the 2016 Alzheimer’s Association International Conference - [at noodls] - Azeliragon MOA designed to inhibit RAGE, which affects Aβ accumulation, tau hyperphosphorylation and chronic inflammation - three of the principal causes of neuronal damage in AD HIGH POINT, N.C.--(BUSINESS ...
07/06/16 06:31 AMvTv Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - HIGH POINT, N.C.--(BUSINESS WIRE)--Jul. 6, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments ...
06/14/16 06:29 AMvTv Therapeutics Presents Positive Results from a Pilot Study of its Glucokinase Activator at American Diabetes Association 76th Scientific Sessions - [at noodls] - Data show TTP399 improves glycemic control and insulin resistance without hypoglycemia NEW ORLEANS--(BUSINESS WIRE)--Jun. 14, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical ...
06/07/16 10:10 AMvTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016 -
05/30/16 06:36 PMVtv Therapeutics Class A (NASDAQ:VTVT) Sellers Increased By 2.17% Their Shorts - HNN - Vtv Therapeutics Class A (NASDAQ:VTVT) Sellers Increased By 2.17% Their ShortsHNNThe short interest to Vtv Therapeutics Class A's float is 3.87%. The stock decreased 1.39% or $0.08 on May 27, hitting $5.66. About 26,454 shares traded hands. vTv Therapeutics Inc (NASDAQ:VTVT) has declined 23.72% since October 22, 2015 and is ...and more »
05/24/16 12:20 PMEarnings Review and Stock Rundown for vTv Therapeutics Inc (NASDAQ:VTVT) - Wall Street Hints and News - Earnings Review and Stock Rundown for vTv Therapeutics Inc (NASDAQ:VTVT)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting vTv Therapeutics Inc (NASDAQ:VTVT) to ...and more »
05/23/16 12:35 PMBiotechnology Lows: vTv Therapeutics Inc. (NASDAQ:VTVT), Jaguar Animal Health (NASDAQ:JAGX), QLT Inc ... - KC Register - Biotechnology Lows: vTv Therapeutics Inc. (NASDAQ:VTVT), Jaguar Animal Health (NASDAQ:JAGX), QLT Inc ...KC RegistervTv Therapeutics Inc. (NASDAQ:VTVT) reported financial and operational results for the first quarter ended March 31, 2016. General and administrative expenses were $2.6 million in the first quarter of 2016, compared to $2.0 million in the same period ...and more »
05/23/16 12:35 PMBest Stocks: Mad Catz Interactive (NYSEMKT:MCZ), vTv Therapeutics Inc. (NASDAQ:VTVT), Ultratech, (NASDAQ:UTEK ... - KC Register - Best Stocks: Mad Catz Interactive (NYSEMKT:MCZ), vTv Therapeutics Inc. (NASDAQ:VTVT), Ultratech, (NASDAQ:UTEK ...KC RegistervTv Therapeutics Inc. (NASDAQ:VTVT) reported financial and operational results for the first quarter ended March 31, 2016. Cash, cash equivalents and marketable securities as of March 31, 2016 were $75.5 million, compared to $88.0 million as of ...
05/21/16 12:54 PMRevenue Update on vTv Therapeutics Inc(NASDAQ:VTVT) - Trade Calls - Revenue Update on vTv Therapeutics Inc(NASDAQ:VTVT)Trade CallsvTv Therapeutics Inc(NASDAQ:VTVT) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 12, 2016. Company reported revenue of $376.00K. Analysts estimated a revenue of $30.00K. Earnings per ...Could vTv Therapeutics Inc Gain Strenght? The Stock Reaches 52-Week LowFranklin Independentall 2 news articles »
05/18/16 12:43 PMShare Recap and Earnings Focus on vTv Therapeutics Inc (NASDAQ:VTVT) - Wall Street Hints and News - Share Recap and Earnings Focus on vTv Therapeutics Inc (NASDAQ:VTVT)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating vTv Therapeutics Inc ...and more »
05/16/16 03:02 PMVTV THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/12/16 04:27 PMvTv Therapeutics Reports First Quarter Financial and Operational Results - [at noodls] - HIGH POINT, N.C.--(BUSINESS WIRE)--May 12, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments ...
05/12/16 03:52 PMVTv Therapeutics reports 1Q loss -
04/27/16 12:32 PMvTv Therapeutics Inc (NASDAQ:VTVT) Share Rating Recap - B.O.D.Y Confidential - vTv Therapeutics Inc (NASDAQ:VTVT) Share Rating RecapB.O.D.Y ConfidentialShares of vTv Therapeutics Inc (NASDAQ:VTVT) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...and more »
04/23/16 11:47 AMvTv Therapeutics Inc (NASDAQ:VTVT) Analyst Rating Review - B.O.D.Y Confidential - vTv Therapeutics Inc (NASDAQ:VTVT) Analyst Rating ReviewB.O.D.Y ConfidentialCovering analysts typically give Buy, Sell and Hold recommendations along with guidance and company earnings projections. Currently, there are 4 analysts that have provided ratings for vTv Therapeutics Inc (NASDAQ:VTVT). 4 have rated the stock a ...and more »
04/22/16 12:31 PMvTv Therapeutics Inc (NASDAQ:VTVT) Share Rating Recap - The Post - vTv Therapeutics Inc (NASDAQ:VTVT) Share Rating RecapThe PostShares of vTv Therapeutics Inc (NASDAQ:VTVT) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...and more »
04/22/16 12:31 PMRecently Changed Price Targets On VTv Therapeutics Inc. (VTVT) - Risers & Fallers - Recently Changed Price Targets On VTv Therapeutics Inc. (VTVT)Risers & Fallers08/24/2015 – Piper Jaffray began new coverage on vTv Therapeutics Inc. giving the company a “overweight” rating. They now have a USD 24 price target on the stock. The share price of vTv Therapeutics Inc. (VTVT) was unchanged +0.00% during the last ...vTv Therapeutics Inc's Stock Is Sell After Forming Bearish Wedge DownCCH Daily Newsall 2 news articles »
04/21/16 12:21 PMBroker Roundup For VTv Therapeutics Inc. (VTVT) - Share Trading News - Broker Roundup For VTv Therapeutics Inc. (VTVT)Share Trading News08/24/2015 – Piper Jaffray began new coverage on vTv Therapeutics Inc. giving the company a “overweight” rating. They now have a USD 24 price target on the stock. The share price of vTv Therapeutics Inc. (VTVT) was down -3.25% during the last trading ...
04/20/16 11:54 AMEither Analysts Got The Components Wrong or Russell 2000 Headed 12% Higher - LBIO), and vTv Therapeutics Inc (Symbol: VTVT). Although UUUU has traded at a recent price of $2.37/share, the average analyst target is 231.65% higher at $7.86/share. Similarly, LBIO has 221.55% upside from the recent share price of $5.66 if the average ...
04/20/16 06:10 AMvTv Therapeutics Presents Data on Two Diabetes Candidates at Keystone Symposia on New Therapeutics for Diabetes and Obesity - [at noodls] - Data featured in an oral presentation show TTP273 is the first GLP-1R agonist without significant gastrointestinal side effects HIGH POINT, N.C.--(BUSINESS WIRE)--Apr. 20, 2016-- vTv Therapeutics Inc. ...
04/19/16 11:51 AMDoes vTv Therapeutics Inc Have Any Gas After Forming This Wedge Down Chart Pattern? - RiversideGazette.com - Does vTv Therapeutics Inc Have Any Gas After Forming This Wedge Down Chart Pattern?RiversideGazette.comThe stock of vTv Therapeutics Inc (VTVT) formed a down wedge with $5.35 target or 12.00% below today's $6.08 share price. The 9 months wedge indicates high risk for the $215.71 million company. If the $5.35 price target is reached, the company will be ...
04/12/16 06:24 AMvTv Therapeutics Announces Presentations on its Diabetes Product Candidates TTP273 and TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity - [at noodls] - HIGH POINT, N.C.--(BUSINESS WIRE)--Apr. 12, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments ...
04/10/16 12:01 PMPtc Therapeutics Incorporated (NASDAQ:PTCT) Short Interest Decreased By 3.37% - Out of 4 analysts covering vTv Therapeutics Inc (NASDAQ:VTVT), 4 rate it "Buy", 0 "Sell", while 0 "Hold". 02/18/2016 - Dimension Therapeutics, Inc. had its "buy" rating reiterated by analysts at Cantor Fitzgerald. Many Wall Street Analysts have commented ...
04/08/16 12:00 PMInsiders Keep on Selling Facebook and Ford - On April 5, Ronald O. Perelman, 10% owner of vTv Therapeutics Inc. (VTVT), bought 400,000 company shares for $5.20 per share. Since then, the price of the stock has dropped by 3.3% to $5.03. The company has an institutional ownership of 20.61% and insider ...
04/06/16 08:50 AMvTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: 2015 By the Numbers -
04/06/16 06:29 AMvTv Therapeutics to Present at the 15th Annual Needham Healthcare Conference - [at noodls] - HIGH POINT, N.C.--(BUSINESS WIRE)--Apr. 6, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments ...
03/21/16 03:01 PMVTV THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers -
03/10/16 12:04 PMVTV THERAPEUTICS INC. Financials -
03/04/16 10:38 AMVTV THERAPEUTICS INC. Files SEC form 10-K, Annual Report -
03/04/16 09:35 AMvTv Therapeutics to Present at Two Investor Conferences in March - [Business Wire] - vTv Therapeutics Inc. , a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe, President and CEO and Dr.
03/01/16 05:09 PMVTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -
03/01/16 06:15 AMVTv Therapeutics reports 4Q loss -
03/01/16 06:00 AMvTv Therapeutics Reports Fourth Quarter and Full Year 2015 Financial and Operational Results and Recent Highlights - [Business Wire] - vTv Therapeutics Inc. , a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2015.
02/24/16 10:06 AMvTv Therapeutics (VTVT) Announces Presentation of GLP-1R Data at Keystone Symposia - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. vTv Therapeutics Inc. (Nasdaq: VTVT) announced that data from studies of its oral, small molecule GLP-1R agonist were reported at the Keystone Symposia on G-Protein ...
02/23/16 03:02 PMVTV THERAPEUTICS INC. Files SEC form 8-K, Unregistered Sale of Equity Securities -
02/22/16 06:00 AMvTv Therapeutics Reports Preclinical and Clinical Results on its Diabetes Candidate TTP273 - [Business Wire] - vTv Therapeutics Inc. , a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that data from studies of its oral, small molecule GLP-1R agonist were reported at the Keystone Symposia on G-Protein Coupled Receptors: Structure, Signaling and Drug Discovery, held in Keystone, CO February ...
02/18/16 09:35 AMNorth Carolina Entrepreneurs Break $1 Billion Mark for Equity Funding in 2015 - There were two IPOs in 2015: MaxPoint (MXPT) and vTv Therapeutics Inc (VTVT). Twenty-two (22) entrepreneurial companies were involved in mergers, acquisitions or buyout activity. The five largest M&A deals disclosed were: Salix Pharmaceuticals, acquired by ...
02/10/16 09:34 AMBLPH Heartened, More Trouble For CTIC, Remicade Biosimilar Gets FDA Panel Nod - TBRA closed Tuesday's trading at $6.55, up 1.55%. vTv Therapeutics Inc. (VTVT) has completed patient enrollment in its phase 2b clinical trial of TTP399 in patients with Type 2 diabetes. The study, dubbed AGATA, is a six-month multi-center, double-blind ...
02/09/16 03:05 PMvTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes - [Business Wire] - vTv Therapeutics Inc. , a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced the completion of patient enrollment in the Company’s AGATA study, a Phase 2b clinical trial assessing the efficacy and safety of TTP399 in patients with Type 2 diabetes.
02/09/16 11:06 AMHow Did Microsoft’s Stock Respond to 2Q16 Results? -
02/09/16 09:28 AMIs a Surprise Coming for vTv Therapeutics (VTVT) This Earnings Season? - Investors are always looking for stocks that are poised to beat at earnings season and vTv Therapeutics Inc. (VTVT - Snapshot Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
02/02/16 02:14 PMMicrosoft’s Fiscal 2Q16 Earnings Beat Expectations -
02/02/16 09:06 AMWhy Did ServiceNow’s Stock Fall by 20% after the Results? -
01/28/16 03:25 PMvTv Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference - [at noodls] - --(BUSINESS WIRE)--Jan. 28, 2016-- (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, ...

Social

About vTv Therapeutics

vTv Therapeutics logovTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VTVT
  • CUSIP:
Key Metrics:
  • Previous Close: $5.66
  • 50 Day Moving Average: $5.79
  • 200 Day Moving Average: $5.91
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $52.92M
  • Current Year EPS Consensus Estimate: $-2.63 EPS
  • Next Year EPS Consensus Estimate: $-2.11 EPS
Additional Links:
vTv Therapeutics (NASDAQ:VTVT) Chart for Sunday, July, 31, 2016